|
June 27,
2006
PRESS RELEASE
PEGASUS/HEARTVIEW DELIVERS FIRST SHIPMENT OF
55 HEARTVUE 6S SYSTEM ELECTROCARDIOGRAPH UNITS TO CHINA
Palm
Beach Gardens , FL ,
Market Wire, June 27 th , 2006. Pegasus/HeartView,
LLC (Symbol: PGUZ-OTC) today announced that
they have completed an initial shipment of 55 HeartView
6S System units to China . The original sale to Pegasus
PharmGroup, a private B.C.,Canada-based company, encompasses
a total sale of 10,000 units over a ten year period
for a cumulative value of $ 50,000,000 USD. (See the
original Press Release dated February 9 th , 2006, Pegasus/HeartView
Sign Multi-Year Sales Agreement
)
PharmGroup and its marketing subsidiary, Pegasus Lifecare
Inc., will focus their sales efforts of the breakthrough
ECG technology units on the more than 20,000 major hospitals
in China through its extensive distributor network throughout
southern Asia . The first shipment of the HeartVue 6S
System units were specially produced for the Asian markets,
featuring a Chinese interface throughout the software
operating functions.
HeartView, LLC is planning to
exhibit the HeartView 6S System in the upcoming World
Congress of Cardiology, September 2 nd 6 th , 2006
in Barcelona , Spain , where over 25,000 delegates
are expected to attend. This major conference is a
joint meeting of the European Society of Cardiologists
and the World Heart Federation (WHF), and will be a
forum featuring the latest research in cardiology and
heart disease prevention. HeartView will be part of
the Emerging Technologies Showcase at the conference.
The HeartVue 6S System is an advanced electrocardiograph
screening technology for early, non-invasive screening
of heart disease. The technology uses only 4 limb wires
(6 standard ECG leads) from the patient's wrists and
ankles. The device includes proprietary software that
converts the electric conductivity of the cardiac tissue
into a three dimensional color-coded visual picture,
which is simple for physicians to interpret. The ECV
device allows testers to observe the condition of the
heart muscle as well as the intensity of the heart stress
load. The device immediately provides a visual of the
patient's heart and an electrocardiogram, the mainstay
in the screening of acute and chronic heart disease (CHD)
HeartView, LLC, Cleveland , Ohio holds the worldwide
patent, manufacturing and marketing rights of the HeartVue
6S System. An earlier version of this electrocardiograph
screening system has already been cleared for sale in
Europe and there is a patent pending for the device in
the United States .
or more information,
please contact Paul Davey, Investor Services at (778)
389-0915
( Canada ). Email: paul@pegasusbiosciences.com,
or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals
Inc., Palm Beach Florida at (561) 626-9901. Further
For investor information,
contact Paul Davey at (778) 389-0915.
Safe Harbor :
This news
release may include forward-looking statements within
the meaning of Section 27A of the United States Securities
Act of 1933, as amended, and Section 21E of the United
states Securities and Exchange Act of 1934, as amended
with respect to achieving corporate objectives, developing
additional project interests, the Company's analysis
of opportunities in the acquisition and development
of various project interests and certain other matters.
These statements are made under the 'safe
harbor' provisions of the United States Private Securities
Litigation Reform Act of 1995 and involve risks and
uncertainties which could cause actual results to differ
materially from those in the forward-looking statements
herein.
|
